Photo by nci from unsplash
median follow-up was 29 (4–38) months, with the median PFS of 9.8 mo (7.4–12.2). The median OS was not reached, 89.6% of patients were alive. The overall response rate (ORR)… Click to show full abstract
median follow-up was 29 (4–38) months, with the median PFS of 9.8 mo (7.4–12.2). The median OS was not reached, 89.6% of patients were alive. The overall response rate (ORR) was 75% including complete remission (CR) in 44% pts. The progressive disease (PD) was the best response in 10% of pts. The allo-HSCT after Nivo was performed in 14 (29%) pts. Conclusion: Nivolumab is highly efficient in the treatment of r/r cHL with early complete response, B-symptoms and extranodal disease at the treatment initiation being the most significant prognostic factor of PFS duration in our population of patients. The therapy may be discontinued in selected patients with complete remission. Combination of nivo with bendamustine is effective and safe approach for patients with r/r cHL after nivo monotherapy failure.
Journal Title: Hematology, Transfusion and Cell Therapy
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!